# Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)

> **NCT00038597** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Myelogenous Leukemia, Chronic

## Interventions

- **DRUG:** SCH66336

## Key facts

- **NCT ID:** NCT00038597
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-04-30
- **Primary completion:** 2004-05-07
- **Final completion:** 2004-05-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2018-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038597, "Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00038597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*